yellow fever vaccine

GPTKB entity

Statements (54)
Predicate Object
gptkbp:instance_of gptkb:vaccine
gptkbp:availability widely available
gptkbp:average_temperature 2 to 8 ° C
gptkbp:clinical_trial Phase I, II, III
gptkbp:community_health reduced incidence of yellow fever
gptkbp:contraindication immunocompromised individuals
egg allergy
pregnancy caution
gptkbp:defense routine vaccination in endemic areas
gptkbp:developed_by gptkb:Max_Theiler
gptkbp:dosage_form recommended after 10 years
gptkbp:duration_of_immunity 10 years
gptkbp:first_introduced 1937
https://www.w3.org/2000/01/rdf-schema#label yellow fever vaccine
gptkbp:is_recommended_for travelers to endemic areas
gptkbp:is_vulnerable_to gptkb:historical_significance
varies by region
ongoing studies
post-marketing surveillance
95% or higher
requires cold chain
CDC guidelines
important for travelers
part of global health initiatives
attenuated live virus
developed from 17 D strain
generally safe for healthy individuals
high in endemic regions
international travel clinics
monitoring adverse effects
prevention of outbreaks
single dose sufficient
single injection
gptkbp:manufacturer multiple pharmaceutical companies
gptkbp:regulatory_compliance FDA approved
gptkbp:route_of_administration subcutaneous
gptkbp:side_effect headache
muscle pain
mild fever
serious allergic reactions
gptkbp:targets gptkb:yellow_fever
gptkbp:trade gptkb:YF-Vax
gptkbp:type live attenuated vaccine
gptkbp:vaccine_administration_age recommended for 9 months and older
gptkbp:vaccine_effectiveness_duration at least 10 years
gptkbp:vaccine_history_significance contributed to public health advancements
gptkbp:vaccine_impact_on_travel required for entry into certain countries
gptkbp:vaccine_public_health_policy integrated into national immunization programs
gptkbp:vaccine_recommendations_for_travel specific countries require vaccination
gptkbp:vaccine_research_focus improving efficacy and safety
gptkbp:bfsParent gptkb:GAVI
gptkb:GAVI,_the_Vaccine_Alliance
gptkb:Flavivirus
gptkbp:bfsLayer 5